Latest Conference Coverage

Gene Therapy Shows Promise for Parkinson Disease

VY-AADC01 demonstrated promising early signs of activity and safety for patients with Parkinson disease.

Kate Davis, MD, MSTR: Cognitive Issues In Epilepsy

The assistant professor of neurology at the University of Pennsylvania discussed the complication of cognitive issues faced by patients with epilepsy, and how these are being addressed in the clinic.

Isabelle Lambert, MD: Spike, Spindle Frequency in Hippocampus During NREM Affect Long-Term Memory

Impairment of physiological spindle activity in the hippocampus during NREM sleep by interictal epileptic activities may have negative consequences on long-term memory consolidation.

Claire Henchcliffe, MD, DPhil: The History of Stem Cell Therapies for Parkinson Disease

Henchcliffe discussed the progress that has been made in this area, and where things are headed going forward.

Novel Agents on the Horizon for Huntington Disease

Several novel therapies in early stage development are beginning to show promise for patients with Huntington disease.

Jeff Waugh, MD, PhD: Using Imaging to Discern the Cause of Diseases

The director of the Pediatric Movement Disorders Program at UT Southwestern spoke about the ability of advanced imaging to help better understand the causes of disease.

The Progress of Micro-Dystrophin Gene Therapy

Since the inception of the idea more than 3 decades ago and its initial development 20 years later, Sarepta Therapeutics’ micro-dystrophin gene therapy has now made its way to human trials.

Rick Wassing, MSc, PhD-C: Restless REM Sleep Contributes to Hyperarousal In Insomnia

Those suffering from significant emotional distress and sleep disturbances may benefit from targeted interventions to restore consolidated REM sleep or prevent the occurrence of fragmented REM sleep.

Thomas Leist, MD: Resetting the Immune System With Cladribine

The director of the Comprehensive Multiple Sclerosis Center at Thomas Jefferson University discussed the concept of lymphocyte depletion to reset the immune system.

Hideki Garren, MD, PhD: Measuring MS Progression With Floodlight Open

The smartphone application-led program, Floodlight Open, recently initiated in the US and Canada.

Teriflunomide Slows Brain Atrophy In Patients At Risk for MS Conversion

Results suggested that for every 1% of brain volume lost, a 51.7% increase in risk of clinically definite MS conversion was observed.

Richard Rudick, MD: The CogEval App in Clinical Practice

The goal of the free application is to make cognitive assessments routine in multiple sclerosis treatment.

Remyelination As The Next Frontier in Multiple Sclerosis

The next important area of therapeutic development in MS appears to be in disease damage repair.

Alemtuzumab Shows Continuous Long-Term Effect on Multiple Sclerosis

The monoclonal antibody has shown continued success up to 8 years in clinical trials.

Peter Calabresi, MD: Clinically Validating Neurofilament Light

One of the highly debated topics at ECTRIMS 2018 was the use of the investigational biomarker, neurofilament light, in the clinic.

John Corboy, MD: The DISCO-MS Trial

The professor of neurology at Colorado University spoke about the ongoing phase IV trial to determine the safety of DMT discontinuation in MS.

Cell Therapies Offer Hope But Are Often Misused

Cellular therapies have the potential to make a meaningful difference for patients with neurological disorders, if used correctly.

IncobotulinumtoxinA Reduces Sialorrhea Across Neurological Disorders

IncobotulinumtoxinA significantly reduced unstimulated salivary flow rate for patients with sialorrhea.

Evobrutinib Significantly Reduces T1 Gd+ Lesions in Relapsing Multiple Sclerosis

This marks the first time a BTK inhibitor showed a clinical proof-of-concept in relapsing MS.

Fernando Dangond, MD, MBA: Evobrutinib for Relapsing Multiple Sclerosis

The Head of Global Clinical Development in Neurology at EMD Serono provided insight into the therapy's performance in phase IIb.

Thomas Leist, MD: Immune Reconstitution Therapy for Multiple Sclerosis

The director of Thomas Jefferson's Comprehensive Multiple Sclerosis Center spoke about the introduction of this treatment method into MS.

Patisiran Shows Sustained Improvements in Disease Progression for hATTR Amyloidosis

Patisiran maintained improvements in mNIS+7 and rapidly halted neurologic disease progression in hATTR amyloidosis.

Robert J. Fox, MD: Neurofilament Light as a Biomarker of Treatment Response

The staff neurologist at Cleveland Clinic’s Mellen Center for Multiple Sclerosis spoke about the current understanding of the biomarker.

Hideki Garren, MD, PhD: The ORATORIO-HAND Trial in PPMS

The Global Head of Neuroimmunology at Genentech discussed the upcoming phase III trial of ocrelizumab while on-site at ECTRIMS 2018.

Cladribine Tablets Safety Profile Reaffirmed With Long-Term Data

An updated safety analysis of the therapy in patients with relapsing MS, up to 10 years, has shown no new safety signals.

Subcutaneous Immunoglobulin Effective Alternative to Intravenous for Myasthenia Gravis

Subcutaneous immunoglobulin is an effective and well-tolerated alternative to intravenous immunoglobulin for myasthenia gravis.

Eculizumab's Myasthenia Gravis Benefits Sustained in Long-Term Extension Study

Eculizumab showed sustained activity and tolerability through 3 years for generalized myasthenia gravis.

Richard Rudick, MD: Using Data to Personalize MS Care

The vice president of Medical Research at Biogen spoke about the intersection between high-quality data utilization and individualized medicine in multiple sclerosis.

John Corboy, MD: Taking Patients Off Of Disease-Modifying Therapy

The professor of neurology at the University of Colorado posited that if certain criteria are met, it could be appropriate to take patients with multiple sclerosis off of DMT.

Earlier Treatment With Ocrelizumab Shows Favorable Results in Relapsing, Primary Progressive MS

Data from multiple open-label extension trials have suggested that the therapy is more beneficial with earlier initiation compared to interferon ß-1a.